

MAR 3 1 2006

K060542

**Attachment B:**  
*Summary of Safety and Effectiveness*  
*Prepared in accordance with 21 CFR Part 807.92(c).*



GE Medical Systems

General Electric Company  
P.O. Box 414, Milwaukee, WI 53201

**Section a):**

1. Submitter: GE Medical Systems, Ultrasound and Primary Care Diagnostics, LLC  
PO Box 414, Milwaukee, WI 53201  
  
Contact Person: Allen Schuh,  
Manager, Safety and Regulatory Engineering  
Telephone: 414-647-4385; Fax: 414-647-4090  
  
Date Prepared: February 28, 2006
2. Device Name: GE Vivid 7 Diagnostic Ultrasound System with EchoPAC BT06  
Ultrasonic Pulsed Echo Imaging System, 21 CFR 892.1560, 90-IYO  
Ultrasonic Pulsed Doppler Imaging System, 21 CFR 892.1550, 90-IYN  
Diagnostic Ultrasonic Transducer, 21 CFR 892.1570, 90-ITX
3. Marketed Device: GE Vivid 7 Diagnostic Ultrasound System K003931/K031663/K041552/K051449  
(90-IYO/IYN/ITX) A device currently in commercial distribution.
4. Device Description: The GE Vivid 7 Diagnostic Ultrasound is a full featured echocardiography imaging and analysis system. It consists of a mobile console approximately 65 cm wide, 96 cm deep and 139 cm high that provides digital acquisition, processing and display capability. The user interface includes a computer keyboard, specialized controls and a color video CRT or LCD display. This modification offers improved performance and productivity for users.
5. Indications for Use: The device is intended for use by a qualified physician for ultrasound evaluation of Fetal; Abdominal (including renal and GYN); Pediatric; Small Organ (breast, testes, thyroid); Neonatal Cephalic; Adult Cephalic; Cardiac (adult and pediatric); Peripheral Vascular (PV); Musculo-skeletal Conventional; Urology (including prostate), Transesophageal; Transrectal (TR); Transvaginal (TV); and Intraoperative (abdominal, thoracic, & vascular).
6. Comparison with Predicate Device: The GE Vivid 7 BT06 is of a comparable type and substantially equivalent to the current GE Vivid 7 with enhanced cardiac analysis and display capability and alternate image display options. It has the same overall characteristics, key safety and effectiveness features, physical design, construction, and materials, and has the same intended uses and operating modes as the predicate device.

**Section b):**

1. Non-clinical Tests: The device has been evaluated for acoustic output, biocompatibility, cleaning and disinfection effectiveness, electromagnetic compatibility, as well as thermal, electrical and mechanical safety, and has been found to conform with applicable medical device safety standards.
2. Clinical Tests: None required.
3. Conclusion: Intended uses and other key features are consistent with traditional clinical practice, FDA guidelines, and established methods of patient examination. The design and development process of the manufacturer conforms with 21 CFR 820, ISO 9001:2000 and ISO 13485 quality systems. The device conforms to applicable medical device safety standards and compliance is verified through independent evaluation with ongoing factory surveillance. Diagnostic ultrasound has accumulated a long history of safe and effective performance. Therefore, it is the opinion of GE Healthcare that the GE Vivid 7 BT06 Diagnostic Ultrasound is substantially equivalent with respect to safety and effectiveness to devices currently cleared for market.



MAR 3 1 2006

Food and Drug Administration  
9200 Corporate Boulevard  
Rockville MD 20850

Mr. Allen Schuh  
Manager, GE Ultrasound Safety and Regulatory Engineering  
GE Medical Systems  
Ultrasound and Primary Care Diagnostics, LLC  
4855 West Electric Avenue  
WEST MILWAUKEE WI 53219

Re: K060542

Trade Name: GE Vivid 7 Ultrasound System  
Regulation Number: 21 CFR 892.1550  
Regulation Name: Ultrasonic pulsed doppler imaging system  
Regulation Number: 21 CFR 892.1560  
Regulation Name: Ultrasonic pulsed echo imaging system  
Regulation Number: 21 CFR 892.1570  
Regulation Name: Diagnostic ultrasonic transducer  
Regulatory Class: II  
Product Code: IYN, IYO, and ITX  
Dated: February 28, 2006  
Received: March 1, 2006

Dear Mr. Schuh:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

This determination of substantial equivalence applies to the following transducers intended for use with the GE Vivid 7 Ultrasound System, as described in your premarket notification:



*Protecting and Promoting Public Health*

Transducer Model Number

9L  
3V

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This determination of substantial equivalence is granted on the condition that prior to shipping the first device, you submit a postclearance special report. This report should contain complete information, including acoustic output measurements based on production line devices, requested in Appendix G, (enclosed) of the Center's September 30, 1997 "Information for Manufacturers Seeking Marketing Clearance of Diagnostic Ultrasound Systems and Transducers." If the special report is incomplete or contains unacceptable values (e.g., acoustic output greater than approved levels), then the 510(k) clearance may not apply to the production units which as a result may be considered adulterated or misbranded.

The special report should reference the manufacturer's 510(k) number. It should be clearly and prominently marked "ADD-TO-FILE" and should be submitted in duplicate to:

Food and Drug Administration  
Center for Devices and Radiological Health  
Document Mail Center (HFZ-401)  
9200 Corporate Boulevard  
Rockville, Maryland 20850


This letter will allow you to begin marketing your device as described in your premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus permits your device to proceed to market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0120. Also, please note the regulation entitled,

"Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address <http://www.fda.gov/cdrh/industry/support/index.html>

If you have any questions regarding the content of this letter, please contact Andrew Kang, M.D. at (301) 594-1212.

Sincerely yours,

A handwritten signature in black ink, appearing to read "Nancy C. Brogdon". To the left of the signature is a small, stylized handwritten mark that looks like "NCT".

Nancy C. Brogdon  
Director, Division of Reproductive,  
Abdominal and Radiological Devices  
Office of Device Evaluation  
Center for Devices and Radiological Health

Enclosure(s)

**Diagnostic Ultrasound Indications for Use Form**

**GE Vivid 7 Ultrasound System**

Intended Use: Diagnostic ultrasound imaging or fluid flow analysis of the human body as follows:

Clinical Application <i>Anatomy/Region of Interest</i>	Mode of Operation										
	B	M	PW Doppler	CW Doppler	Color Doppler	Color M Doppler	Power Doppler	Combined Modes	Harmonic Imaging	Coded Pulse	RT3D Mode*
Ophthalmic											
Fetal / Obstetrics	P	P	P	P	P	P	P	P	P	P	P
Abdominal <sup>[1]</sup>	P	P	P	P	P	P	P	P	P	P	P
Pediatric	P	P	P	P	P	P	P	P	P	P	P
Small Organ <sup>[2]</sup>	P	P	P		P	P	P	P	P	P	
Neonatal Cephalic	P	P	P	P	P	P	P	P	P	P	
Adult Cephalic	P	P	P	P	P	P	P	P	P	P	P
Cardiac <sup>[3]</sup>	P	P	P	P	P	P	P	P	P	P	P
Peripheral Vascular	P	P	P	P	P	P	P	P	P	P	
Musculo-skeletal Conventional	P	P	P		P	P	P	P	P	P	
Musculo-skeletal Superficial											
Other <sup>[4]</sup>	P	P	P	P	P	P	P	P	P	P	P
<i>Exam Type, Means of Access</i>											
Transesophageal	P	P	P	P	P	P	P	P	P	P	
Transrectal	P	P	P		P	P	P	P		P	
Transvaginal	P	P	P		P	P	P	P		P	
Transurethral											
Intraoperative <sup>[5]</sup>	P	P	P		P	P	P	P		P	
Intraoperative Neurological											
Intravascular											
Laparoscopic											

N = new indication; P = previously cleared by FDA; E = added under Appendix E

Notes: [1] Abdominal includes renal, GYN/Pelvic

[2] Small organ includes breast, testes, thyroid.

[3] Cardiac is Adult and Pediatric.

[4] Other use includes Urology/Prostate


[5] Intraoperative includes abdominal, thoracic (cardiac), and vascular (PV).

[\*] Combined modes are B/M, B/Color M, B/PWD or CWD, B/Color/PWD or CWD, B/Power/PWD.

[\*] RT3D is Realtime 3D / 4D volume tissue scan acquisition (with or w/o color flow);

(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

  
 (Division Sign-Off)  
 Division of Reproductive, Abdominal,  
 and Radiological Devices  
 510(k) Number K060542

Prescription User (Per 21 CFR 801.109)

Special 510(k) Premarket Notification  
GE Healthcare - GE Vivid 7 and EchoPAC BT06  
February 28, 2006

**Diagnostic Ultrasound Indications for Use Form**

**GE Vivid 7 with 9L Transducer**

Intended Use: Diagnostic ultrasound imaging or fluid flow analysis of the human body as follows:

Clinical Application Anatomy/Region of Interest	Mode of Operation										
	B	M	PW Doppler	CW Doppler	Color Doppler	Color M Doppler	Power Doppler	Combined Modes*	Harmonic Imaging	Coded Pulse	
Ophthalmic											
Fetal / Obstetrics											
Abdominal											
Pediatric	N	N	N		N	N	N	N	N	N	
Small Organ <sup>[2]</sup>	N	N	N		N	N	N	N	N	N	
Neonatal Cephalic											
Adult Cephalic											
Cardiac											
Peripheral Vascular	N	N	N		N	N	N	N	N	N	
Musculo-skeletal Conventional	N	N	N		N	N	N	N	N	N	
Musculo-skeletal Superficial											
Other <sup>[4]</sup>											
Exam Type, Means of Access											
Transesophageal											
Transrectal											
Transvaginal											
Transurethral											
Intraoperative (specify)											
Intraoperative Neurological											
Intravascular											
Laparoscopic											

N = new indication; P = previously cleared by FDA; E = added under Appendix E


Notes: [2] Small organ includes breast, testes, thyroid.

[\*] Combined modes are B/M, B/Color M, B/PWD, B/Color/PWD, B/Power/PWD.

(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Prescription User (Per 21 CFR 801.109)

  
(Division Sign-Off)  
Division of Reproductive, Abdominal,  
and Radiological Devices  
510(k) Number 2060542

**Diagnostic Ultrasound Indications for Use Form**

**GE Vivid 7 with 3V Transducer**

Intended Use: Diagnostic ultrasound imaging or fluid flow analysis of the human body as follows:

Clinical Application Anatomy/ Region of Interest	Mode of Operation										
	B	M	PW Doppler	CW Doppler	Color Doppler	Color M Doppler	Power Doppler	Combined Modes	Harmonic Imaging	Coded Pulse	RT3D Mode*
Ophthalmic											
Fetal / Obstetrics	P	P	P	P	P	P	P	P	P	P	P
Abdominal	P	P	P	P	P	P	P	P	P	P	P
Pediatric	P	P	P	P	P	P	P	P	P	P	P
Small Organ (specify)											
Neonatal Cephalic											
Adult Cephalic	P	P	P	P	P	P	P	P	P	P	P
Cardiac	P	P	P	P	P	P	P	P	P	P	P
Peripheral Vascular											
Musculo-skeletal Conventional											
Musculo-skeletal Superficial											
Other (specify) <sup>[4]</sup>	P	P	P	P	P	P	P	P	P	P	P
Exam Type, Means of Access											
Transesophageal											
Transrectal											
Transvaginal											
Transurethral											
Intraoperative											
Intraoperative Neurological											
Intravascular											
Laparoscopic											

N = new indication; P = previously cleared by FDA; E = added under Appendix E

Notes: [\*] Combined modes are B/M, B/Color M, B/PWD, B/Color/PWD, B/Power/PWD.


[\*] RT3D is Realtime 3D / 4D volume tissue scan acquisition (with or w/o color flow);

[3] Cardiac is Adult and Pediatric

[4] Other use includes Urology;

(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

  
 (Division Sign-Off)

Division of Reproductive, Abdominal,  
 and Radiological Devices

510(k) Number

K060542

Prescription User (Per 21 CFR 801.109)